Continuing tirzepatide treatment, even at lower doses, successfully maintains weight loss over the long term, according to new research that challenges the assumption that maximum doses are always necessary for sustained results. The SURMOUNT-MAINTAIN trial found that people who stayed on tirzepatide at either the standard maximum dose or a reduced 5 mg dose kept off significantly more weight than those who stopped treatment entirely, offering doctors and patients a more personalized approach to managing obesity.

What Happens When You Stop Taking Tirzepatide?

Researchers enrolled 441 adults with obesity in the United States and tracked them over 112 weeks. After an initial 60-week period where everyone took tirzepatide weekly by injection, participants who had lost at least 5% of their body weight were randomly assigned to one of three groups: continue tirzepatide at the maximum tolerated dose (10 or 15 mg), continue at a reduced dose of 5 mg, or switch to placebo.

The results were striking. By the end of the study, people taking the maximum dose had lost 21.9% of their baseline body weight, while those on the 5 mg dose lost 16.6%. In sharp contrast, the placebo group lost only 9.9% of their starting weight. The difference between continuing treatment and stopping it was substantial: only 8% of people on the maximum dose and 25% on the reduced dose regained at least half of what they had lost, compared with 67% of those who switched to placebo.

These findings matter because they suggest that obesity, like diabetes or high blood pressure, may require ongoing treatment to maintain results. "Combined, these findings underscore the importance of continued therapy for long-term obesity management and provide evidence for what to expect when reducing the intensity of obesity treatment," noted the study authors.

Can You Use a Lower Dose and Still See Results?

One of the most practical insights from this research is that the lowest effective dose may be sufficient for weight maintenance, even if higher doses were needed initially to achieve weight loss. The 5 mg dose maintained meaningful results without requiring the maximum dose that some patients find difficult to tolerate due to side effects.

All participants received ongoing lifestyle support throughout the trial, including dietary counseling and physical activity guidance. This combination of medication plus behavioral support appears to be key to long-term success. Notably, the study allowed rescue treatment with tirzepatide for participants who regained more than half their weight loss, starting at 24 weeks into the maintenance phase. This safety net meant that even if someone struggled, they could resume higher doses if needed.

Beyond weight loss, tirzepatide improved other health markers in both dose groups. Participants showed improvements in body mass index (BMI), waist circumference, blood sugar control, blood pressure, and cholesterol levels compared to placebo.

How to Approach Long-Term Tirzepatide Treatment

• Dose Flexibility: Work with your doctor to find the lowest dose that maintains your weight loss, rather than assuming you need to stay on the maximum dose indefinitely. The 5 mg maintenance dose proved effective for many participants.
• Ongoing Lifestyle Support: Continue dietary counseling and physical activity as part of your treatment plan. The study participants who succeeded combined medication with behavioral changes throughout the entire trial period.
• Regular Monitoring: Stay in close contact with your healthcare provider to track weight changes and adjust your dose if needed. The study protocol allowed for rescue treatment if weight regain exceeded 50% of initial loss.
• Expect Mild Side Effects: Gastrointestinal issues like nausea, vomiting, and diarrhea were the most common adverse events, particularly at higher doses. These typically improve over time and may be less bothersome at reduced doses.

The safety profile was reassuring. During the 52-week maintenance phase, only three serious adverse events were reported across all treatment groups, and the overall adverse event rate was higher with tirzepatide than placebo, but mostly consisted of mild-to-moderate gastrointestinal symptoms.

What Does This Mean for Obesity Treatment?

For years, obesity treatment has followed a pattern: lose weight through intensive intervention, then hope the weight stays off. This trial suggests a different model. "The clinical rationale for continuing pharmacotherapy at the lowest effective dose for weight maintenance has been acknowledged, but without specific evidence for low-dose regimens, individualized approaches and further research have been called for," explained André J. Scheen, MD, in an accompanying editorial comment on the research.

The participants in this study had lived with obesity for a median of 13 years and had tried unsuccessfully to lose weight before enrolling. Their average age was 47, and 65% were women. The baseline average weight was 251 pounds, with a BMI of 40.1 (considered severe obesity). These were people with significant, long-standing weight challenges, making the sustained results even more meaningful.

The research opens the door to more personalized obesity management. Rather than a one-size-fits-all approach, doctors can now consider whether patients might maintain results on a lower, potentially better-tolerated dose. This could make tirzepatide treatment more sustainable for more people over the long term, addressing one of the biggest challenges in obesity care: keeping weight off after initial loss.